260 related articles for article (PubMed ID: 16684427)
1. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
2. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
3. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
5. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
Mizukami A; Kaise T; Van Kriekinge G
Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
[TBL] [Abstract][Full Text] [Related]
6. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
Dasbach EJ; Insinga RP; Elbasha EH
BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
[TBL] [Abstract][Full Text] [Related]
7. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland.
Coles VA; Chapman R; Lanitis T; Carroll SM
Int J STD AIDS; 2016 Jan; 27(1):51-7. PubMed ID: 25681263
[TBL] [Abstract][Full Text] [Related]
8. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
Herse F; Reissell E
Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
[TBL] [Abstract][Full Text] [Related]
9. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
10. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
11. The cost of managing genital warts in the UK.
Lanitis T; Carroll S; O'Mahony C; Charman F; Khalid JM; Griffiths V; Brown RE
Int J STD AIDS; 2012 Mar; 23(3):189-94. PubMed ID: 22581873
[TBL] [Abstract][Full Text] [Related]
12. Health and economic burden of HPV-related diseases in Singapore.
Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and cost of treatment of genital warts in Spain.
Castellsagué X; Cohet C; Puig-Tintoré LM; Acebes LO; Salinas J; San Martin M; Breitscheidel L; Rémy V
Eur J Public Health; 2009 Jan; 19(1):106-10. PubMed ID: 19112075
[TBL] [Abstract][Full Text] [Related]
14. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M; Van de Velde N; De Wals P; Boily MC
Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
[TBL] [Abstract][Full Text] [Related]
15. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
16. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
17. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost?
Melnikow J; Birch S
J Natl Cancer Inst; 2006 Jan; 98(2):82-3. PubMed ID: 16418504
[No Abstract] [Full Text] [Related]
20. Age-based programs for vaccination against HPV.
Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
